Prazosin
- Molecular formula
- C19H21N5O4
- CAS Number
- 19237-84-4
- IUPAC Name
- [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2-bicyclo[2.2.2]octa-2,5-dienyl)methanone
- Molecular Weight
- 383.41g/mol
- Melting Point
- (Celsius)
- Boiling Point
- (Celsius)
- Density
- 1.3500g/cm3
- Synonyms
- Prazobind
Identification
Exploring [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2-bicyclo[2.2.2]octa-2,5-dienyl)methanone
This compound is a fascinating example of modern medicinal chemistry, particularly due to its structural complexity and potential pharmacological applications. Here are some interesting facts:
- Quinazoline Derivative: The compound contains a quinazoline moiety, which plays a significant role in drug design. Quinazolines are known for their diverse biological activities, including anticancer, antimicrobial, and antiviral effects.
- Piperazine Linker: The presence of a piperazine group contributes to the compound’s ability to interact with various biological targets, enhancing its pharmacodynamics.
- Unique Bicyclic Structure: The bicyclo[2.2.2]octane framework introduces strain, which can stabilize or influence the bioactivity of the compound significantly.
- Potential Therapeutic Uses: Given its unique structure, this compound is being researched for use in treatments against a variety of conditions, including but not limited to cancer and neurological disorders.
The intricate balance of the piperazine and quinazoline elements within this compound showcases the intricate relationship between chemical structure and biological function. As noted by many chemists, "The structure of a molecule is the key to unlocking its potential." This statement holds particularly true for compounds with complex architectures like [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2-bicyclo[2.2.2]octa-2,5-dienyl)methanone, which push the boundaries of our understanding of molecular interactions in pharmaceuticals.
Research continues to unfold the potential of such compounds in developing new therapeutic agents, highlighting the continual need for innovation in the field of drug discovery.